Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasudil and PD-1 Inhibitor with ADT in Neoadjuvant Prostate Cancer
NCT06861192Phase 3Recruiting
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fasudil and toripalimab in prostate cancer (PCa) (2 arms). Primary endpoint: Pathological Complete Response or Minimal Residual Disease Rate up to 4 weeks. Started Feb 2025; status: recruiting.
02
Drugs
fasudiltoripalimab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06861192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861192.